Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
December 14 2018 - 9:00AM
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the
pricing of its underwritten public offering of 30,000,000 of its
common shares at a price to the public of $1.00 per
share. Gross proceeds to Axovant from the offering are expected to
be approximately $30,000,000 before deducting underwriting
discounts and commissions and estimated offering expenses. All
of the common shares are being offered by Axovant. In connection
with this offering, Axovant has granted the underwriters a 30-day
option to purchase up to an additional 4,500,000 of its common
shares on the same terms and conditions. The offering is expected
to close on December 18, 2018, subject to customary closing
conditions.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the offering. JMP Securities is acting as
lead manager and H.C. Wainwright & Co. is acting as co-manager
for the offering.
A shelf registration statement relating to the offered common
shares was filed with the Securities and Exchange Commission (SEC),
and was declared effective on January 13, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the
SEC's website, located at www.sec.gov. Copies of the final
prospectus supplement and accompanying base prospectus related to
the offering may be obtained, when available, from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by e-mail at Prospectus_Department@Jefferies.com; and
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, New York, NY 10017, or by telephone at (212)
518-9658, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant Axovant is a clinical-stage
gene therapy company focused on developing a pipeline of innovative
product candidates for debilitating neurological and neuromuscular
diseases such as Parkinson's disease, GM1 gangliosidosis, Tay-Sachs
and Sandhoff diseases, oculopharyngeal muscular dystrophy (OPMD),
amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and
other indications. For more information, visit www.axovant.com
SOURCE Axovant Sciences
Contacts:
Investors
Tricia Truehart(631) 892-7014investors@axovant.com
Media
Lara Yuan(646) 802-3585media@axovant.com
Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From Apr 2023 to Apr 2024